Respiratory syncytial virus is the second most common respiratory illness in adults behind the flu. Although most people who get RSV will have mild, cold-like symptoms, it can be more serious for babies, the elderly, and those with weakened immune systems. Severe RSV can lead to pneumonia or worsened symptoms of chronic obstructive pulmonary disease (COPD) or congestive heart failure (CHF). We are conducting this study to see if an investigational vaccine can help produce antibodies and cells to fight off RSV infections in older adults.
By taking part in this clinical trial, you can help advance vaccines across the globe. Your participation represents your community as well as all people who are affected by RSV.